The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered (Q27015045)

Anna N. Cvrljevic

series ordinal

2

1 reference

Terrance G. Johns

series ordinal

3

1 reference

language of work or name

1 reference

November 2013

1 reference

1 reference

280

1 reference

PubMed

issue

21

1 reference

PubMed

page(s)

5350-70

1 reference

Epidermal growth factor receptor dependence in human tumors: more than just expression?

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Autophosphorylation sites on the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor stimulation of diacylglycerol kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Profile of differentially expressed genes mediated by the type III epidermal growth factor receptor mutation expressed in a small-cell lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

EGFRvIII-mediated radioresistance through a strong cytoprotective response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

19F- and fluorescently labeled micelles as nanoscopic assemblies for chemotherapeutic delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor 1 (EGFR1) and its variant EGFRvIII regulate TATA-binding protein expression through distinct pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Genetically engineered T cells to target EGFRvIII expressing glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Mutant epidermal growth factor receptor vIII increases cell motility and clonogenecity in a prostate cell line RWPE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

EGFR and EGFRvIII expression in primary breast cancer and cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

A new antibody recognizing the vIII mutation of human epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Single transmembrane spanning heterotrimeric g protein-coupled receptors and their signaling cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

The EGFRvIII variant in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Expression of constitutively activated EGFRvIII in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Activation of STAT proteins and growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Function of aberrant EGFR in malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

IkappaBalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Cumulative influence of matrix metalloproteinase-1 and -2 in the migration of melanoma cells within three-dimensional type I collagen lattices

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Forced dimerization increases the activity of ΔEGFR/EGFRvIII and enhances its oncogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Increased lipogenesis in cancer cells: new players, novel targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

AMPK phosphorylation of raptor mediates a metabolic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12393

https://api.fatcat.wiki/v0/release/x65vp6tyk5awrlfptts3rhuwlm

21 January 2018

Identifiers

1 reference

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_x65vp6tyk5awrlfptts3rhuwlm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x65vp6tyk5awrlfptts3rhuwlm

mapped directly with Wikidata item

30 July 2022

based on heuristic

OpenCitations bibliographic resource ID

54079

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

https://api.fatcat.wiki/v0/release/x65vp6tyk5awrlfptts3rhuwlm